Skip to content

US · AMGN · DRUG MANUFACTURERS - GENERAL

Amgen Inc. (AMGN) intrinsic value and stock valuation

$435.64as of 2026-11-21 · Mkt cap 220.11B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Amgen Inc. DCF and intrinsic value

InvestorsCraft values AMGN with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from AMGN’s statements →

Amgen Inc. Graham Number

Graham Number: $72.04d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - General Thousand Oaks, CA 91320-1799 amgen.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$36.7B+7.6% 5y CAGRd
20112025
Net income
$7.71B+1.2% 5y CAGRd
20112025
Free cash flow
$8.1B-3.9% 5y CAGRd
20112025
Total equity
$8.66B-1.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$36.7B$33.4B$28.2B$26.3B$26B
Operating income$10.7B$7.26B$7.9B$9.57B$7.64B
Net income$7.71B$4.09B$6.72B$6.55B$5.89B
EPSd$14.2M$7.56M$12.5M$12.1M$10.3M
Operating cash flow$9.96B$11.5B$8.47B$9.72B$9.26B
Capital expenditure-$-1.86B-$-1.1B-$-1.11B-$-936M-$-880M
Free cash flow$8.1B$10.4B$7.36B$8.79B$8.38B
Total assets$90.6B$91.8B$97.2B$65.1B$61.2B
Total debt$54.6B$60.1B$64.6B$38.9B$33.3B
Net debt$45.5B$48.1B$53.7B$31.3B$25.3B
Total equity$8.66B$5.88B$6.23B$3.66B$6.7B
Cash and short-term investments$9.13B$12B$10.9B$9.31B$8.04B
Income statement
20252024202320222021
Revenue$36.7B$33.4B$28.2B$26.3B$26B
Cost of revenue$10.7B$12.9B$8.42B$6.41B$6.45B
Gross profit$26B$20.6B$19.8B$19.9B$19.5B
Research and development expenses$6.97B$5.96B$4.78B$4.43B$6.32B
Selling, general and administrative expenses$7.05B$7.1B$6.18B$5.41B$5.37B
Other expenses$1.31B$248M$879M$503M$194M
Operating expenses$15.3B$13.3B$11.8B$10.4B$11.9B
Cost and expenses$26.1B$26.2B$20.3B$16.8B$18.3B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$2.76B$3.16B$2.88B$1.41B$1.2B
Depreciation and amortization$5.17B$5.59B$4.07B$3.42B$3.4B
Ebitda$16.9B$13.4B$14.8B$12.2B$11.3B
Operating income$10.7B$7.26B$7.9B$9.57B$7.64B
Total other income/expenses, net-$-1.7B-$-2.65B-$-42M-$-2.22B-$-938M
Income before tax$8.98B$4.61B$7.86B$7.35B$6.7B
Income tax expense$1.27B$519M$1.14B$794M$808M
Net income$7.71B$4.09B$6.72B$6.55B$5.89B
Weighted average shares outstanding$538M$541M$535M$538M$570M
Weighted average diluted shares outstanding$542M$541M$538M$541M$573M
Balance sheet
20252024202320222021
Cash and short-term investments$9.13B$12B$10.9B$9.31B$8.04B
Net receivables$9.57B$7.5B$7.94B$6.39B$5.84B
Inventory$6.23B$7B$9.52B$4.93B$4.09B
Total current assets$29.1B$29B$30.3B$22.2B$19.4B
Property, plant and equipment, net$8.52B$6.54B$5.94B$5.43B$5.18B
Goodwill and intangible assets$41B$46.3B$51.3B$31.6B$30.1B
Long-term investments$6.8B$5.36B$4.71B$0.00$0.00
Total non-current assets$61.5B$62.8B$66.8B$42.9B$41.8B
Total assets$90.6B$91.8B$97.2B$65.1B$61.2B
Accounts payable$2.37B$1.91B$1.59B$1.57B$1.37B
Short-term debt$4.6B$3.55B$1.44B$1.59B$87M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$25.5B$23.1B$18.4B$15.7B$12.2B
Long-term debt$50B$56.5B$63.2B$37.4B$33.2B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$56.4B$62.9B$72.5B$45.8B$42.3B
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$81.9B$86B$90.9B$61.5B$54.5B
Common stock$34B$33.5B$33.1B$32.5B$32.1B
Retained earnings-$-25.11B-$-27.59B-$-26.55B-$-28.62B-$-24.6B
Accumulated other comprehensive income (loss)-$-258M-$-66M-$-289M-$-231M-$-796M
Total equity$8.66B$5.88B$6.23B$3.66B$6.7B
Total investments$6.8B$5.36B$4.71B$1.68B$48M
Total debt$54.6B$60.1B$64.6B$38.9B$33.3B
Net debt$45.5B$48.1B$53.7B$31.3B$25.3B
Cash flow statement
20252024202320222021
Net income$7.71B$4.09B$6.72B$6.55B$5.89B
Depreciation and amortization$5.17B$5.59B$4.07B$3.42B$3.4B
Stock-based compensation$494M$530M$431M$401M$341M
Change in working capital-$-1.98B$2.37B-$-484M-$-733M-$-1.19B
Accounts receivable-$-2.68B$441M-$-1.02B-$-746M-$-429M
Inventory$886M$2.53B$491M-$-742M-$-165M
Accounts payable$428M$312M-$-402M$154M-$-69M
Net cash provided by operating activities$9.96B$11.5B$8.47B$9.72B$9.26B
Investments in property, plant and equipment-$-1.86B-$-1.1B-$-1.11B-$-936M-$-880M
Acquisitions, net-$-53M$0.00-$-26.99B-$-3.73B-$-2.69B
Net cash used for investing activities-$-1.94B-$-1.05B-$-26.2B-$-6.04B$733M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased$0.00-$-200M$0.00-$-6.36B-$-4.98B
Dividends paid-$-5.12B-$-4.83B-$-4.56B-$-4.2B-$-4.01B
Net cash used for financing activities-$-10.86B-$-9.42B$21B-$-4.04B-$-8.27B
Net change in cash-$-2.84B$1.03B$3.32B-$-360M$1.72B
Cash at end of period$9.13B$12B$10.9B$7.63B$7.99B
Operating cash flow$9.96B$11.5B$8.47B$9.72B$9.26B
Capital expenditure-$-1.86B-$-1.1B-$-1.11B-$-936M-$-880M
Free cash flow$8.1B$10.4B$7.36B$8.79B$8.38B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Amgen Inc.

        Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

        CEO
        Robert A. Bradway
        Employees
        31.5K
        Beta
        0.40

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Amgen Inc. (AMGN)?

        Amgen Inc. (AMGN) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is AMGN undervalued?

        AMGN trades at a price of $435.64 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.